Oruka Therapeutics, Inc. ORKA Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation?
- Oruka Therapeutics, Inc. (ORKA) reported cash provided by (used in) operating activity, including discontinued operation of -$23.58M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
- Oruka Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation decreased by 13.0% year-over-year, from -$20.87M to -$23.58M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation?
- Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation has grown at a 47.3% compound annual growth rate (CAGR), from -$18.76M to -$88.21M.
- What does cash provided by (used in) operating activity, including discontinued operation mean?
- Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.